ClinicalTrials.gg
Active, not recruitingNCT07764757Updated Aug 20, 2026

Platelet-Rich Fibrin as an Antibiotic Delivery Vehicle in Mandibular Third Molar Surgery

An interventional study of Antibiotic-enriched Platelet-Rich Fibrin (PRF) and Platelet-Rich Fibrin (PRF) in Facial Swelling, Tooth Position Anomalies and Tooth, Impacted, sponsored by Amerigo Giudice. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Amerigo Giudice · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Nov 2025, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 32 Years
Sex
All
01

Study summary

The present study aims to evaluate the effect of platelet-rich fibrin (PRF) used as a local antibiotic delivery vehicle on postoperative outcomes, including facial swelling, trismus, and pain, following mandibular third molar surgery in a randomized split-mouth clinical trial.

02

Conditions studied

  • Facial Swelling
  • Tooth Position Anomalies
  • Tooth, Impacted
  • Tooth Extraction Status Nos
  • Tooth Avulsion

Browse trials for

Keywords

  • third molar surgery
  • facial swelling
  • 3D facial swelling evaluation
  • PRF
  • tooth impacted
  • platelet rich fibrin
  • antibiotic delivery
03

In context

Tooth, Impacted

122 studies on the registry are indexed under Tooth, Impacted; 15 are open to participants now.

This study's enrollment of 31 is below the median of 70 across 88 interventional studies indexed under Tooth, Impacted.

Browse Tooth, Impacted studies →

Lead sponsor

Amerigo Giudice is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 32 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy patients () according to the American Society of Anesthesiologists classification.
  • Age 18-32 years.
  • Ability to provide written .
  • Bilateral mandibular third molars requiring extraction for prophylactic, therapeutic, or strategic reasons.
  • Complete root development of mandibular third molars (Shumaker Stage H).
  • Availability of diagnostic-quality CBCT scans with adequate field of view (17 × 20).
  • Mandibular third molars classified as having conventional or moderate surgical difficulty according to Juodzbalys and Daugela classification.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to .
  • or immunocompromised conditions.
  • Acute infection at the mandibular third molar extraction sites.
  • Current or previous intravenous amino-bisphosphonate therapy.
  • Psychiatric disorders.
  • Thrombocytopenia ( count \<40,000/µL), thrombocytosis, or other coagulation disorders.
  • Severe hepatic cirrhosis, advanced chronic renal failure, or uncontrolled -diabetes mellitus.
  • Pregnancy or breastfeeding.
  • Requirement for additional regenerative procedures (e.g., bone grafting).
  • Localized facial malformations involving the cheek region.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Test Group - Antibiotic and PRF

    Participants will receive platelet-rich fibrin prepared with the addition of antibiotic prior to centrifugation. The antibiotic-enriched PRF clot will be placed into the mandibular third molar extraction socket to provide local antibiotic delivery at the surgical site.

    Biological: Antibiotic-enriched Platelet-Rich Fibrin (PRF)

  • Active comparator
    Control Group - PRF only

    Participants will receive standard platelet-rich fibrin prepared without antibiotic addition. The PRF clot will be placed into the mandibular third molar extraction socket according to the same surgical protocol.

    Biological: Platelet-Rich Fibrin (PRF)

Interventions

  • BiologicalAntibiotic-enriched Platelet-Rich Fibrin (PRF)

    Platelet-rich fibrin prepared with the addition of antibiotic prior to centrifugation and applied into the mandibular third molar extraction socket to provide local antibiotic delivery.

  • Standard platelet-rich fibrin prepared without antibiotic addition and applied into the mandibular third molar extraction socket.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative infection

    Occurrence of postoperative infection following mandibular third molar surgery, assessed through clinical examination based on the presence of signs and symptoms of infection (e.g., purulent discharge, erythema, fever, or need for additional antibiotic therapy).

    Time frame: Up to 7 days after surgery

  2. Facial swelling qualitative analysis

    Change in facial volume from baseline, assessed by three-dimensional facial scan superimposition and expressed as colorimetric variation between the preoperative and postoperative scans.

    Time frame: Change from baseline (before surgery) at 2 day after surgery and at 7 days after surgery

  3. Facial swelling quantitative analysis - volumetric differences

    To compare postoperative facial swelling between treatment groups using quantitative three-dimensional analysis based on volumetric differences. Facial volume changes will be measured in cubic centimeters (cm³) through three-dimensional facial scan superimposition.

    Time frame: Change from baseline (before surgery) at 2 day after surgery and at 7 days after surgery

  4. Facial swelling quantitative analysis - linear differences

    To compare postoperative facial swelling between treatment groups using quantitative three-dimensional analysis based on linear measurements. Facial changes will be assessed by evaluating linear differences (mm) between preoperative and postoperative three-dimensional facial scans.

    Time frame: Change from baseline (before surgery) at 2 day after surgery and at 7 days after surgery

Secondary outcomes

  1. Trismus analysis

    To compare postoperative limitation of mouth opening between treatment groups following mandibular third molar surgery. Trismus will be assessed by measuring maximum mouth opening (MMO) in millimeters (mm).

    Time frame: Change from baseline (before surgery) at 2 day after surgery and at 7 days after surgery

  2. Pain analysis with Visual analogue scale (VAS)

    To compare postoperative pain intensity between treatment groups following mandibular third molar surgery. Pain will be assessed using a Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Change from baseline (before surgery) at 2 day after surgery and at 7 days after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764757
Lead sponsor
Amerigo Giudice
Responsible party
Amerigo Giudice (Professor, University Magna Graecia) — Sponsor-investigator
First posted
Aug 14, 2026
Start date
Nov 1, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: P-prf

Start the discussion